FDA Says It Is Investigating Potential Link Between Vytorin and Risk of Cancer (MRK, SGP)
More News related to MRK
- Vical (VICL) Receives $1M Milestone Payment from Merck (MRK) for Initiation of Phase I Trial of DNA Cancer Vaccine
- Merck & Co. (MRK) Declares $0.38/Sh Qtr Dividend
- Merck Announces First Quarter 2009 Dividend
- NASDAQ OMX and Leerink Swann to Co-Host Healthcare Industry Forum
- Merck to Hold Guidance Conference Call and Web Cast on Dec. 4
More News related to SGP
- Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
- Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
- Schering-Plough (SGP) Unveils Top-Line Results on SAPHRIS(TM) Showing Efficacy and Safety in Preventing Relapse of Schizophrenia; Reports Preladenant Met Primary Endpoints in Phase II Trial
- Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
- Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
More News related to Corporate News
- Boyd Gaming (BYD) CFO Buys 10K Shares
- Lumber Liquidators (LL) Founder/Chairman Sullivan Sold 282K Shares
- Zale (ZLC) Sees Heavy Insider Buying As Stock Hits New Low
- ION Geophysical (IO) Director Buys 50K Shares
- Sunstone Hotel Investors (SHO) CFO Buys 20K Shares
The U.S. FDA has posted information on its website that it is reviewing potential cancer risks related to cholesterol drugs. The agency cites a report of a possible link in study of Merck (NYSE: MRK) and Schering-Plough's (NYSE: SGP) Vytorin.
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally.
Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-1.87Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
